Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508026 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,161
- Enrollment target
NCT01508026 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 4,161 participants.
The verdict
NCT01508026, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,161 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
Interventions
- DRUG Nebivolol and Valsartan 1
- DRUG Nebivolol and Valsartan 2
- DRUG Nebivolol and Valsartan 3
- DRUG Nebivolol 1
- DRUG Nebivolol 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,161 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508026
The ClinicalTrials.gov registry entry for NCT01508026 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nebivolol and Valsartan 1 is the first listed.
NCT01508026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508026 about?
NCT01508026 is a clinical study titled "Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension". To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
What is the current status of trial NCT01508026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,161 participants. The study started on 2012-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01508026?
The interventions under investigation include: Nebivolol and Valsartan 1 (DRUG), Nebivolol and Valsartan 2 (DRUG), Nebivolol and Valsartan 3 (DRUG), Nebivolol 1 (DRUG), Nebivolol 2 (DRUG).
Who is sponsoring clinical trial NCT01508026?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.